Preparing for Next Big One

SK bioscience CEO Ahn Jae-yong (third from left) and Thailand’s Government Pharmaceutical Organization director Mingkwan Suphanpong (second from left) pose for a photo after signing a memorandum of understanding on vaccine collaboration in Nonthaburi, north of Bangkok, on July 4, 2023.
SK bioscience CEO Ahn Jae-yong (third from left) and Thailand’s Government Pharmaceutical Organization director Mingkwan Suphanpong (second from left) pose for a photo after signing a memorandum of understanding on vaccine collaboration in Nonthaburi, north of Bangkok, on July 4, 2023.

On Aug. 21, SK bioscience announced that it had signed a contract with Thailand’s state-run pharmaceutical company GPO to supply SkyCellflu, a cell-cultured influenza vaccine concentrate, valued at 679.9 billion won.

Following the MOU with GPO last month for the establishment of local vaccine production and development infrastructure, SK bioscience also entered into a contract to transfer the production technology for SKYCellflu.

SK bioscience will supply the vaccine concentrate to GPO through a Thai company, BGT. SK bioscience plans to collaborate with GPO in the medium to long term to promote vaccine localization in Thailand and the ASEAN region and to build infrastructure to respond to new pandemics.

Copyright © BusinessKorea. Prohibited from unauthorized reproduction and redistribution